Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
In July 2020, the Phase 2a/b VIVIAD study began to enroll 259 early stage Alzheimer’s patients in Denmark, Germany, and The Netherlands. A 24-week dose finding phase is testing 300 or 600 mg twice daily versus placebo, followed by up to 96 weeks treatment at the highest safe dose. The primary endpoints are safety, and efficacy on working memory and attention. Secondary endpoints include long-term safety and effects on brain activity, cognition, and daily functioning. The trial is also collecting exploratory data on the Winterlight speech-based cognitive assessment, EEG, and blood biomarkers. For more details, see the published protocol (Vijverberg et al., 2021). In November 2021, Vivoryon began another Phase 2a/b trial, this time in the U.S., and in collaboration with the U.S. National Institutes on Aging and the Alzheimer’s Disease Cooperative Study. The VIVA-MIND study is enrolling 414 participants with biomarker-confirmed early AD and MMSE scores between 20 and 30. The initial part of this safety and efficacy trial will titrate 180 patients in three groups to target doses of 150 mg, 300 mg, or 600 mg twice a day for at least 24 weeks, or placebo. Primary outcomes are safety, plasma levels, ADNI cognitive battery composite scores, and quantitative EEG. Based on the results, investigators will calculate target occupancy in CNS, and continue dosing these and additional participants at a level aiming for 50 percent occupancy for 72 weeks, or placebo. The primary efficacy outcome is change in CDR-Sum of Boxes from baseline to 72 weeks; secondary outcomes include the cognitive function composite CFC2 score. Study completion is expected in November 2023. In December 2021, the U.S. FDA granted Fast Track status to varoglutamstat. In June 2022, the company announced completion of the dose-finding phase of VIVIAD. Based on data from 181 patients, an independent safety monitoring board selected the highest dose tested, 600 mg twice daily, for the rest of the study (press release). Trial results are expected in the second half of 2023.
Het essentiele pathway om de ziekte te bestrijden blijft wazig.Nu heeft prof De Strooper een nieuw target ontdekt.Goed resultaat bij ....muizen Belgische wetenschappers doen belangrijke ontdekking in onderzoek naar Alzheimer: “Cruciale stap vooruit” Een onderzoeksteam van VIB-KU Leuven heeft ontdekt hoe zenuwcellen afsterven en kan het probleem zelfs voorkomen. Dat is een belangrijke stap naar de mogelijke behandeling van de ziekte van Alzheimer. De bevindingen van Doctor Sriram Balusu en professor Bart De Strooper, die ook verbonden is aan het UK Dementia Research Institute, zijn gepubliceerd in het wetenschappelijk tijdschrift Science. Alzheimer wordt wellicht onder andere veroorzaakt door de opeenhoping van ‘amyloïde’, een soort eiwit, tussen de zenuwcellen in de hersenen. Eerdere experimenten op muizen gaven nooit duidelijke antwoorden over hoe de ziekte juist te werk ging. Dat kwam omdat muizen beter bestand zijn tegen die zogenaamde ‘amyloïde pathologie’, zo blijkt. Wetenschappers botsten dan ook op de limieten van de onderzoeken met muizen, die bepaalde kenmerken van de ziekte niet natuurgetrouw kunnen nabootsen De onderzoekers hebben nu een nieuw model ontwikkeld, waarbij gezonde zenuwcellen van mensen en muizen in het brein van Alzheimer-muismodellen - lees: muizen waarin het ziektepatroon van Alzheimer wordt nagebootst - worden ingebracht. Dat nieuwe model leidde wél tot belangrijke inzichten. Zo werd een geprogrammeerde vorm van celdood, die bekend staat als necroptose, geactiveerd. Dat leidde tot de dood van neuronen. De onderzoekers zagen dat de aanwezigheid van een bepaalde molecule - genaamd ‘MEG3' - sterk verhoogd was in menselijke neuronen, net zoals bij Alzheimerpatiënten. De aanwezigheid van MEG3 alleen al zorgde ervoor dat de menselijke neuronen in een labsetting afstierven. Bovendien slaagde het onderzoeksteam erin het afsterven van neuronen te voorkomen, wat nieuwe mogelijkheden biedt voor toekomstige behandelingen. Door MEG3 te verminderen - en dus necroptose te vermijden - zijn de onderzoekers erin geslaagd om celdood te vermijden. “Meer onderzoek is nodig om exact te begrijpen hoe MEG3 necroptose in gang zet, maar de ontdekking is een cruciale stap vooruit om te begrijpen hoe Alzheimer tot verlies van neuronen in de hersenen leidt”, aldus het VIB (Vlaams Instituut voor Biotechnologie). De bevindingen zijn cruciaal om de ziekte te begrijpen en een behandeling te ontwerpen. Een proces dat mogelijk nog jaren in beslag zal nemen.
Diede schreef op 19 oktober 2023 15:27: Coverage Initiation: Vivoryon: SELL - 1 € Another swing and a miss in AD? Initiating with a SELL ahead of the phase 2b readout During 2023, the amyloid hypothesis was clearly validated with the full approval of lecanemab. Vivoryon's varoglutamstat, which inhibits amyloid plaque formation but doesn't clear existing one, showed limited to no efficacy in a short phase 2a study with significant non-adherence. While the drug is under evaluation in two phase 2 trials (VIVA-MIND in the US and VIVIAD in the EU), we believe that the VIVIAD trial is likely to fail when topline results will be reported in Q1 2024. We initiate coverage with a SELL and a EUR 1 PT. Koers dus van €1 door een analist van Bryan Garnier
DeZwarteRidder schreef op 17 februari 2021 10:48 :
[...]
Vergeet dat maar: fase 2A was zeer slecht, dus de vooruitzichten voor Vivo zijn nog slechter.
.
Bayer Clears Early Hurdle With Gene Therapy for Parkinson’s By Tim Loh January 4, 2024 at 2:46 AM EST Bayer AG said that its gene therapy against Parkinson’s disease succeeded in an early-stage trial, allowing the German company to start with a phase-II study of the medicine in coming months. The therapy was well tolerated in 11 patients with no serious adverse events after 18 months, according to a statement Thursday.www.bloomberg.com/news/articles/2024-
Improvements with simufilam A scheduled interim safety review in late 2023 didn’t raise any noteworthy issues with the two trials and interim data from REFOCUS-ALZ hinted that simufilam may not carry the safety risks seen with other recently Alzheimer’s medications. Antibody-based treatments targeting amyloid-beta can cause swelling in the brain, known as ARIA-E (amyloid-related imaging abnormalities edema). An interim analysis of MRI data from 180 patients in REFOCUS-ALZ showed none had ARIA-E after 40 weeks, about 10 months. The analysis noted some instances of bleeding in the brain, known as ARIA-H, but the rates were low; about 5% of patients who didn’t have bleeding when they entered the trial had new bleeding at week 40. That’s consistent with rates of brain bleeding in patients who aren’t on treatment, so it’s unlikely these bleeds are from simufilam, according to Cassava. Alzheimer’s disease is characterized by toxic clumps of proteins in the brain, such as amyloid-beta and tau, which may contribute to its progression. Simufilam is designed to target filamin A, a protein that forms abnormal clumps in Alzheimer’s and that’s also involved in amyloid-beta and tau clumping. By targeting filamin A, simufilam seeks to reduce brain damage and slow disease progression. It’s also thought to have anti-inflammatory effects. Simufilam was tested in a Phase 2 clinical trial (NCT04388254) that enrolled 216 people with mild to moderate Alzheimer’s disease. For the first part, all participants were treated with simufilam (100 mg twice daily) for a year. Topline results from the first part involving 157 patients showed nearly half saw improvements in cognition, based on the ADAS-Cog11 , which is similar to ADAS-Cog12. In the next part, the participants were randomly assigned to continue taking simufilam or switch to a placebo for six months. Results showed that average ADAS-Cog11 scores worsened by 0.9 points with simufilam and by 1.5 points with a placebo.That works out to a 38% difference favoring simufilam, though it wasn’t statistically significant, meaning it’s plausible the difference could be due to chance. Phase 2 studies, which primarily assess safety, often don’t have a large enough sample size to detect statistically meaningful results, which is why the Phase 3 trials include nearly 2,000 patients.
www.iex.nl/Nieuws/786371/Vivoryon-ver... Hier wachten beleggers op. De uitkomst zal mede bepalend zijn voor de voortgang en de koers. Zit in de wachtkamer.
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease VIVIAD Phase 2b study did not meet its primary and key secondary endpoints Varoglutamstat was generally well tolerated with low discontinuation rates due to adverse events and no evidence of symptomatic ARIAs in the clinical setting VIVIAD is a comprehensive, diligently designed and high-quality study; baseline demographics in the study were highly representative of early AD patient population Company is conducting an in-depth analysis of the results, including analyses of additional pre-specified and exploratory endpoints Further update expected to be provided no later than with publication of Company’s full year 2023 financial results Halle (Saale) / Munich, Germany, March 4, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced topline results from its Phase 2b European VIVIAD study of varoglutamstat (PQ912), an investigational oral glutaminyl cyclase (QPCT) inhibitor in development for the treatment of early Alzheimer’s disease (AD). The VIVIAD study did not meet its primary endpoint and did not show a statistically significant difference in change over time on cognition, as measured by a combined score (Z-score) of the Detection test, the Identification test and the ‘One Back’ test (attention and working memory domains) of the Cogstate neuropsychological test battery (NTB), called “Cogstate 3-item scale”. Additionally, the study did not meet key secondary endpoints measuring cognition (Cogstate Brief Battery, CBB, and complete Cogstate NTB), Instrumental Activities of Daily Living Questionnaire (A-IADL-Q) and electroencephalogram (EEG) global theta power. Varoglutamstat was generally well tolerated and showed rates similar to placebo of serious and severe treatment emergent adverse events (TEAEs), low discontinuation rates due to adverse events and no evidence of symptomatic ARIAs (amyloid-related imaging abnormalities) in the clinical setting. The Company is conducting an in-depth analysis of the results, including analyses of additional pre-specified exploratory endpoints (e.g. WAIS-IV coding test, executive function and episodic memory domains, Winterlight Labs speech assessment, cerebrospinal fluid (CSF) biomarkers and additional EEG analysis) and distinct patient cohorts as defined in the statistical analysis plan, including ApoE4 status, tau level, dose level and pre-treatment. “We are profoundly disappointed by the outcome of the VIVIAD Phase 2b study of varoglutamstat in the early AD patient population given the huge unmet need for new safe and effective oral therapies,” said Frank Weber, M.D., CEO of Vivoryon. “I would like to express our gratitude to the patients, their families and caregivers, as well as the investigators for participating in the VIVIAD study, and to our incredible team at Vivoryon for their tireless efforts. While these results are not what we had hoped for, VIVIAD is a comprehensive, diligently designed and high-quality study and we are doing all we can to fully analyze the dataset as quickly as possible to gain insights into key findings that might influence varoglutamstat clinical development and help advance the science and understanding of this devastating disease.” A further update is expected to be provided no later than with the publication of the Company’s full year 2023 financial results which are expected in mid to late April 2024.
DeZwarteRidder schreef op 19 oktober 2023 15:32 :
Diede schreef op 19 oktober 2023 15:27:
Coverage Initiation: Vivoryon: SELL - 1 €
Another swing and a miss in AD? Initiating with a SELL ahead of the phase 2b readout
During 2023, the amyloid hypothesis was clearly validated with the full approval of lecanemab. Vivoryon's varoglutamstat, which inhibits amyloid plaque formation but doesn't clear existing one, showed limited to no efficacy in a short phase 2a study with significant non-adherence. While the drug is under evaluation in two phase 2 trials (VIVA-MIND in the US and VIVIAD in the EU), we believe that the VIVIAD trial is likely to fail when topline results will be reported in Q1 2024. We initiate coverage with a SELL and a EUR 1 PT.
Koers dus van €1 door een analist van Bryan Garnier
Het zou me niet verbazen als Bryan Garnier en Janus een bepaalde voorkennnis hebben gehad, alhoewel ze hun mening baseren op hetzelfde als ik, nl fase 2A.
in het ongunstigste scenario kan de koers nu dalen naar 1 euro, als Vivoryon besluit te stoppen met de klinische ontwikkeling van het middel. Tijd voor herstel en gokje nemen en straks instappen.
Diegy zit er al naast....
Diegy schreef op 4 maart 2024 12:36 :
in het ongunstigste scenario kan de koers nu dalen naar 1 euro, als Vivoryon besluit te stoppen met de klinische ontwikkeling van het middel.
Tijd voor herstel en gokje nemen en straks instappen.
Hoe kom je toch aan dit soort onzin.....??? De koers staat nu op 50 cent.
Kooporder geplaatst op 0,47 cent.
Diegy schreef op 4 maart 2024 12:38 :
Kooporder geplaatst op 0,47 cent.
Beetje gierig..
Diegy schreef op 4 maart 2024 12:36 :
in het ongunstigste scenario kan de koers nu dalen naar 1 euro, als Vivoryon besluit te stoppen met de klinische ontwikkeling van het middel.
Tijd voor herstel en gokje nemen en straks instappen.
Ik dacht dat het koersverloop van Philips een fiasco was maar het kan nog altijd veel erger zie ik hier.
DeZwarteRidder schreef op 19 oktober 2023 15:32 :
Diede schreef op 19 oktober 2023 15:27:
Coverage Initiation: Vivoryon: SELL - 1 €
Another swing and a miss in AD? Initiating with a SELL ahead of the phase 2b readout
During 2023, the amyloid hypothesis was clearly validated with the full approval of lecanemab. Vivoryon's varoglutamstat, which inhibits amyloid plaque formation but doesn't clear existing one, showed limited to no efficacy in a short phase 2a study with significant non-adherence. While the drug is under evaluation in two phase 2 trials (VIVA-MIND in the US and VIVIAD in the EU), we believe that the VIVIAD trial is likely to fail when topline results will be reported in Q1 2024. We initiate coverage with a SELL and a EUR 1 PT.
Koers dus van €1 door een analist van Bryan Garnier
Het peperdure VIVA-MIND programma in de USA zal onvermijdelijk op korte termijn stop gezet worden.
Toch benieuwd wie de koper is van 1.575.820 stukkies in het begin...
foexie schreef op 4 maart 2024 12:55 :
Toch benieuwd wie de koper is van 1.575.820 stukkies in het begin...
Waarschijnlijk shortdekking en maak je maar geen illusies dat iemand deze waardeloze tent wil overnemen.
Rowi62 schreef op 4 maart 2024 12:38 :
Diegy zit er al naast....
Eigenlijk is dat niet vermeldenswaardig:-).
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
Nextensa
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee